Non-Myeloablative Stem Cell Transplants Fludarabine In
Total Page：16
File Type：pdf, Size：1020Kb
Bone Marrow Transplantation (2003) 31, 11–15 & 2003 Nature Publishing Group All rights reserved 0268-3369/03 $25.00 www.nature.com/bmt Non-myeloablative stem cell transplants Fludarabine in combination with cyclophosphamide decreases incidence of GVHD and maintains effective graft-versus-leukemia effect after allogeneic stem cell transplantation in murine lymphocytic leukemia L Weiss1, A Abdul-Hai1,ROr1, G Amir2 and A Polliack3 1Department of Bone Marrow Transplantation and Cancer Immunobiology Research Laboratory, Jerusalem, Israel; 2Department of Pathology, Jerusalem, Israel; and 3Department of Hematology, Hadassah University Hospital and Hebrew University, Hadassah Medical School, Jerusalem, Israel Summary: well as in acute leukemia.4–7 Most recently, it has been incorporated into nonmyeloablative cytoreduction regi- Graft-versus-host disease (GVHD) is a severe disorder mens and used as for immunosuppression in the novel and despite therapeutic efforts to decrease its distressing mini-allogeneic transplant procedure used in recent years clinical manifestations, treatment is still not optimal. Here for a variety of hematological disorders.8–10 In fact, we report the results of studies, in which the purine fludarabine is the anchor drug in these regimens. The analogue, fludarabine phosphate, was used in an attempt cytotoxic potential of fludarabine against T lymphocytes, to modify and decrease GVHD after stem cell transplanta- coupled with its immunosuppressive qualities, has made tion, across major histocompatibility barriers for murine it an attractive choice for both chemotherapy and im- leukemia. B-cell leukemia (BCL-1) bearing (BALB/ munomodulation, during allogeneic transplantation for c  C57BL/6) F1 mice received two cycles of fludarabine leukemia.11,12 Indeed, the use of fludarabine-containing (0.8 mg/kg) for 5 days every 2 weeks, followed by 400 mg/ regimens has altered the incidence, and the degree of graft- kg cyclophosphamide i.p. Animals were then transplanted versus-host disease (GVHD) in these patients and this with C57BL/6 precursor cells and the development of regimen is used currently in a number of transplant leukemia and extent of GVHD was monitored both centers.8–13 clinically and histopathologically. In the fludarabine- Despite the impressive results in human hematopoietic treated group, only nine of 28 (32%) mice developed stem cell transplantation, fludarabine has as yet not been leukemia, compared to 25 of 33 (76%) of control animals adequately tested in animal models. In this respect, there is (P ¼ 0.0006 ). Mice treated with fludarabine-containing some recent experimental evidence showing that it may be regimens prior to transplantation also had much less effective in transplantation across histocompatibility GVHD both clinically and at autopsy, while graft-versus- barriers in mice.14 Furthermore, it is also able to induce leukemia appeared to be augmented in the same animals. bilateral tolerance or stable chimerism after marrow or skin Bone Marrow Transplantation (2003) 31, 11–15. transplantation,15 thereby altering the incidence of graft doi:10.1038/sj.bmt.1703775 rejection and the extent of GVHD encountered. In earlier Keywords: fludarabine; cyclophosphamide; graft-versus- pilot murine studies, we were also able to show an anti- host disease incidence; graft-versus-leukemia; hematopoie- GVHD prophylactic effect after marrow transplantation in tic stem cell transplant; murine lymphocytic leukemia mice.16 In the present study, we report the results of a series of experiments using the combination of fludarabine and cyclophosphamide as cytoreduction during allogeneic stem Fludarabine used as a single agent or in combination with cell transplantation for murine leukemia. In these studies, other drugs has been extensively used in recent years for the we attempted to mimic human leukemias clinically and treatment of a variety of hemato-oncologic disorders, and determine whether fludarabine could decrease the intensity has been shown to be most effective in indolent lympho- and incidence of acute GVHD, while preserving or even proliferative disorders, particularly chronic lymphocytic enhancing the simultaneous graft-versus-leukemia (GVL) leukemia (CLL) and follicular lymphoma.1–3 Furthermore, effect in this experimental model. fludarabine-containing combination regimens have also been used in the treatment of aggressive lymphomas as Material and methods Correspondence: Professor A Polliack, Head of Lymphoma–Leukemia Unit, Department of Hematology, Hadassah University Hospital, Ein All animal procedures utilized in the present study were Kerem, PO Box 12000, Jerusalem 91120, Israel approved by the Institutional Committee for Animal Received 29 May 2002; accepted 29 July 2002 Experimentation. Fludarabine and transplantation in murine leukemia L Weiss et al 12 MHC-BMT model mice. This protocol attempted to mimic the clinical situation of partially responsive disease in humans with Male and female mice 2–6 months old (BALB/c C57BL/  leukemia where therapy is followed by allogeneic stem cell 6) F1 (H-2d/b) were transplanted with C57BL/6 (H-2b), transplantation. bone marrow or spleen cells. The mice purchased from the F-1 mice received 105 BCL-1 leukemia cells and 1 day Harlan Breeding Facility (Jerusalem, Israel) were kept in a later 0.8 mg/kg fludarabine was given for 5consecutive standard animal facility with top-filtered cages. Cages, days. After 2 weeks, the mice received another 5days cycle sawdust and water bottles were autoclaved once a week. of 0.8 mg/kg fludarabine, followed by 400 mg/kg i.p. Neomycin sulfate, at a concentration of 0.5%, was given in cyclophosphamide 2 weeks later. A day after the above the drinking water for 2 weeks post-transplantation. treatment with cyclophosphamide, animals were trans- Fludarabine monophosphate (Schering, Berlin, Germany) planted with 10  106 C57BL/6 bone marrow cells and and cyclophosphamide (ASTA medica Ig, Frankfurt/Main, 2  106 spleen cells. Control animals received saline instead Germany) were given intraperitoneally. of fludarabine. The experiments performed with this schedule were repeated on four separate occasions. Stem cell transplantation Experiment 3: This experiment tried to evaluate the effect of fludarabine and allogeneic transplantation com- Bone marrow cells were prepared by flushing RPMI pared to syngeneic transplantation in leukemic mice. F-1 medium through the femora and humeri of donors with a mice were treated with 0.8 mg/kg fludarabine or saline twice 9–25-gauge needle. Spleens were removed aseptically from a week for 2 weeks. The mice were injected with 400 mg/kg donor mice, teased through a nylon mesh into RPMI 1640 cyclo i.p. 10 days later. The mice were transplanted with medium (GIBCO, Grand Island Biological Co., Grand 20  106 C57BL spleen cells or F-1 spleen cells 24 h later. Island, NY, USA) and washed twice. Spleen cells (20  106 The effect of fludarabine on GVHD across major per recipient mouse) were injected intravenously into the histocompatibility (MHC) barriers was assessed in all these lateral tail vein. experiments. Statistical evaluation The t-test was used for comparison between fludarabine- Results treated and control animals. Experiment 1: Four of the 10 mice receiving 0.3 and 0.5mg/kg fludarabine and cyclophosphamide survived Murine B-cell leukemia (BCL-1) more than 2 months. Mice that received 0.5mg/kg BCL-1, as previously described in BALB/c female mice,17 fludarabine only developed leukemia within 45days. Two was maintained in vivo by intravenous (i.v.) passage of 106– of the five mice treated with cyclophosphamide only 107 peripheral blood lymphocytes (PBLs) obtained from survived more than 2 months. In the group of six mice tumor-bearing mice. All untreated recipients of BCL-1 cells receiving 0.7 mg/kg fludarabine and the same dose of (X100 cells) consistently develop splenomegaly followed by cyclophosphamide, three (50%) survived, all control mice marked lymphocytosis in the peripheral blood and all developed leukemia within 34 days (Figure 1). animals die from leukemia.17 PBL counts of all experi- Experiment 2: Figure 2 summarizes the results of four mental groups were carried out weekly. Clinical onset of different experiments. A total of 25out of 33 (76%) control leukemia was defined as PBL counts exceeding 20 000/mm3. animals treated with saline and transplanted with allogeneic stem cells (C57) developed leukemia and died within 60 days, while in the fludarabine-treated group only nine out Monitoring of GVHD of 28 mice (32%) had leukemia within this period Mice were observed daily for survival and clinical signs of (P ¼ 0.006). GVHD, manifested as diarrhoea, weight loss and ruffled skin. In 12 surviving mice treated with fludarabine regimens, autopsy was performed. In these animals without clinical Experimental design evidence of leukemia, histopathology revealed that one had obvious leukemia in the spleen and liver, four had minor Basically, three different protocols were used. minimal residual disease, while seven of 12 had no signs of Experiment 1: This attempted to assess the effect of the leukemia at all. GVHD was either totally absent or minor fludarabine-containing regimens on BCL-1 leukemia in F-1 in the examined group (Figures 3–5). mice without transplant. Of the 33 control mice, only eight had no clinical Mice were injected with 104 BCL-1 leukemia cells and 1 evidence of leukemia. Six of these underwent autopsy, day later received 3 doses of fludarabine (0.3, 0.5, or 0.7 mg/ which showed that five had obvious leukemia